Patents by Inventor Jonas Boström

Jonas Boström has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230348363
    Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.
    Type: Application
    Filed: February 22, 2023
    Publication date: November 2, 2023
    Inventors: Kenneth Lars GRANBERG, Shigeki SAKAMAKI, Ryuichi FUCHIGAMI, Yasuki NIWA, Masakazu FUJIO, Hans Fredrik BERGSTRÖM, Stig Jonas BOSTRÖM, Giulia Bergonzini, Henrik Graden, Lars Johan Andreas Ulander
  • Patent number: 11667602
    Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: June 6, 2023
    Assignees: AstraZeneca AB, MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kenneth Lars Granberg, Shigeki Sakamaki, Ryuichi Fuchigami, Yasuki Niwa, Masakazu Fujio, Hans Fredrik Bergström, Stig Jonas Boström
  • Publication number: 20230078576
    Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 16, 2023
    Inventors: Kenneth Lars GRANBERG, Shigeki SAKAMAKI, Ryuichi FUCHIGAMI, Yasuki NIWA, Masakazu FUJIO, Hans Fredrik BERGSTRÖM, Stig Jonas BOSTRÖM
  • Patent number: 8415378
    Abstract: or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally compris
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: April 9, 2013
    Assignee: AstraZeneca AB
    Inventors: Jonas Boström, Leifeng Cheng, Tomas Fex, Michael Karle, Daniel Pettersen, Peter Schell
  • Patent number: 8361998
    Abstract: The invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, x and y are as defined herein. Compounds according to Formula I are pharmacologically effective as potassium channel inhibitors, in particular inhibitors of the acetylcholine operated inward rectifying potassium channel current (i.e. IKACh blockers), and are believed to be useful in the treatment of cardiac arrhythmias, in particular supraventricular tacharrhythmias, such as atrial fibrillation and atrial flutter.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: January 29, 2013
    Assignee: AstraZeneca AB
    Inventors: Jonas Bostrõm, Hans Emtenäs, Kenneth Granberg, Mickael Mogemark, Antonio Llinas
  • Publication number: 20120142659
    Abstract: The invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, x and y are as defined herein. Compounds according to Formula I are pharmacologically effective as potassium channel inhibitors, in particular inhibitors of the acetylcholine operated inward rectifying potassium channel current (i.e. IKACh blockers), and are believed to be useful in the treatment of cardiac arrhythmias, in particular supraventricular tacharrhythmias, such as atrial fibrillation and atrial flutter.
    Type: Application
    Filed: November 29, 2011
    Publication date: June 7, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Jonas Bostrõm, Hans Emtenäs, Kenneth Granberg, Mickael Mogemark, Antonio Llinas
  • Patent number: 8067584
    Abstract: Compounds of formula: (1) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: November 29, 2011
    Assignee: Albireo AB
    Inventors: Ingemar Starke, Suzanne Alenfalk, Mats Peter Nordberg, Mikael Ulf Johan Dahlstrom, Stig Jonas Bostrom, Malin Anita Lemurell, Andreas Christer Wallberg
  • Publication number: 20100298392
    Abstract: There is provided compounds of formula I, wherein R1 to R7 have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: July 12, 2007
    Publication date: November 25, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Annika Bjore, Jonas Bostrom, Ojvind Davidsson, Hans Emtenas, Ulrik Gran, Tommy Iliefski, Johan Kajanus, Roine Olsson, Lars Sandberg, Gert Strandlund, Johan Sundell, Zhong-Qing Yuan
  • Publication number: 20100261755
    Abstract: or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally comprising
    Type: Application
    Filed: April 6, 2010
    Publication date: October 14, 2010
    Applicant: AstraZeneca AB
    Inventors: Jonas BOSTRÖM, Leifeng Cheng, Tomas Fex, Michael Karle, Daniel Pettersen, Peter Schell
  • Publication number: 20100016321
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: July 23, 2009
    Publication date: January 21, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Jonas Bostrom, Kay Brickmann, Anders Broo, Robert Judkins, Lanna Li, Pernilla Sandberg, Marianne Swanson, Christer Westerlund, Patrik Holm
  • Publication number: 20090227555
    Abstract: The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: June 23, 2008
    Publication date: September 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Peter Bach, Jonas Bostrom, Kay Brickmann, Leifeng Cheng, Fabrizio Giordanetto, Robert Groneberg, Darren Harvey, Michael O'Sullivan, Fredrik Zetterberg
  • Patent number: 7582629
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 9, 2006
    Date of Patent: September 1, 2009
    Assignee: AstraZeneca AB
    Inventors: Jonas Boström, Kay Brickmann, Anders Broo, Robert Judkins, Lanna Li, Pernilla Sandberg, Marianne Swanson, Christer Westerlund, Patrik Holm
  • Publication number: 20090156616
    Abstract: The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: July 17, 2006
    Publication date: June 18, 2009
    Inventors: Jonas Bostrom, Leifeng Cheng, Roine Olsson
  • Publication number: 20090042852
    Abstract: The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: January 4, 2006
    Publication date: February 12, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Peter Bach, Jonas Bostrom, Kay Brickmann, Leifeng Cheng, Fabrizio Giordanetto, Robert D. Groneberg, Darren Martin Harvey, Michael F. O'Sullivan, Fredrik Zetterberg, Krister Osterlund
  • Publication number: 20080255122
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: January 9, 2006
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Jonas Bostrom, Kay Brickmann, Anders Broo, Robert Judkins, Lanna Li, Pernilla Sandberg, Marianne Swanson, Christer Westerlund, Patrik Holm
  • Patent number: 7432288
    Abstract: The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR)?(NR1H3) and/or ?(NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: October 7, 2008
    Assignee: AstraZeneca AB
    Inventors: Jonas Boström, Kay Brickmann, Patrik Holm, Pernilla Sandberg, Marianne Swanson, Christer Westerlund
  • Patent number: 7342019
    Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which R1 and R2 independently represent: a C1-6alkyl group; an optionally substituted (amino)C1-4alkyl-group; an optionally substituted non-aromatic C3-15carbocyclic group; a (C3-12cycloalkyl)C1-3alkyl-group; a group —(CH2)r(phenyl)s in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by Z; naphthyl; anthracenyl; an optionally substituted saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; 1-adamantylmethyl; a group —(CH2)t Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted and Het represents an optionally substituted aromatic heterocycle; or R1 represents H and R2 is as defined above; or R1 and R2 together with the nitrogen atom to which they are atta
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: March 11, 2008
    Assignee: AstraZeneca AB
    Inventors: Anna Ingrid Kristina Berggren, Stig Jonas Boström, Stig Thomas Elebring, Peter Greasley, Emma Terricabras, Johan Michael Wilstermann
  • Publication number: 20080015237
    Abstract: There is provided compounds of formula I, wherein R1 to R7 have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: July 11, 2007
    Publication date: January 17, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Annika Bjore, Jonas Bostrom, Ojvind Davidsson, Hans Emtenas, Ulrik Gran, Tommy Iliefski, Johan Kajanus, Roine Olsson, Gert Strandlund, Johan Sundell, Zhong-Qing Yuan, Lars Sandberg
  • Patent number: 7238684
    Abstract: The present invention relates to compounds of formula (I): wherein Rv, R1, R2, Rx, Ry, R3, R4, R5, R6, Rz and v are as defined within; pharmaceutically acceptable salts, solvates, solvates or such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: July 3, 2007
    Assignee: AstraZeneca AB
    Inventors: Ingemar Starke, Mikael Ulf Johan Dahlstrom, Mats Peter Nordberg, Suzanne Alenfalk, Andreas Christer Wallberg, Stig Jonas Bostrom
  • Patent number: 7192946
    Abstract: The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: March 20, 2007
    Assignee: AstraZeneca AB
    Inventors: Ingemar Starke, Mikael Ulf Johan Dahlstrom, David Blomberg, Suzanne Alenfalk, Peter Nordberg, Andreas Christer Wallberg, Stig Jonas Bostrom